Lisa A. Jackson, MD, MPH

Jackson_Lisa_A_205x293.jpg

“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Lisa A. Jackson, MD, MPH

Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine

Lisa.A.Jackson@kp.org
206-442-5216

Biography

Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991. Dr. Jackson is the Kaiser Permanente Washington Health Research Institute (KPWHRI) principal investigator (PI) for the Vaccine Safety Datalink Project sponsored by the Centers for Disease Control and Prevention (CDC). She is also PI of the KPWHRI Vaccine and Treatment Evaluation Unit network site—one of nine network sites that the National Institutes of Health sponsors.

Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.

After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.

A research professor in the UW Department of Epidemiology, Dr. Jackson is also an adjunct research professor in the UW Department of Medicine.

Research interests and experience

  • Vaccines & Infectious Diseases

    Vaccine  safety; influenza vaccine effectiveness in the elderly; methodologic issues in  vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine  effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly;  epidemiology of E. coli bacteremia; epidemiology of community-acquired  pneumonia

 

Recent publications

Flannery B, Kondor RJG, Chung JR, Gaglani M, Reis M, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Kim SS, Blanton L, Kniss K, Budd AP, Brammer L, Stark TJ, Barnes JR, Wentworth DE, Fry AM, Patel M. Spread of antigenically drifted influenza A(H3N2) viruses and vaccine effectiveness in the United States during the 2018-2019 season. J Infect Dis. 2019 Oct 30. pii: 5609441. doi: 10.1093/infdis/jiz543. [Epub ahead of print]. PubMed

Donahue JG, Kieke BA, King JP, Mascola MA, Shimabukuro TT, DeStefano F, Hanson KE, McClure DL, Olaiya O, Glanz JM, Hechter RC, Irving SA, Jackson LA, Klein NP, Naleway AL, Weintraub ES, Belongia EA. Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15. Vaccine. 2019;37(44):6673-6681. doi: 10.1016/j.vaccine.2019.09.035. Epub 2019 Sep 17. PubMed

Groom HC, Smith N, Irving SA, Koppolu P, Vazquez-Benitez G, Kharbanda EO, Daley MF, Donahue JG, Getahun D, Jackson LA, Klein NP, McCarthy NL, Nordin JD, Panagiotakopoulos L, Naleway AL. Uptake and safety of hepatitis A vaccination during pregnancy: a Vaccine Safety Datalink study. Vaccine. 2019;37(44):6648-6655. doi: 10.1016/j.vaccine.2019.09.043. Epub 2019 Sep 20. PubMed

Cook AJ, Wellman RD, Marsh T, Shoaibi A, Tiwari R, Nguyen M, Boudreau D, Weintraub ES, Jackson L, Nelson JC. Applying sequential surveillance methods that use regression adjustment or weighting to control confounding in a multi-site, rare event, distributed setting: part 2:in-depth example of a re-analysis of the measles-mumps-rubella-varicella combination vacc J Clin Epidemiol. 2019 Sep; 113:114-122. PubMed

Zheng C, Yu W, Xie F, Chen W, Mercado C, Sy LS, Qian L, Glenn S, Lee G, Tseng HF, Duffy J, Jackson LA, Daley MF, Crane B, McLean HQ, Jacobsen SJ. The use of natural language processing to identify Tdap-related local reactions at five health care systems in the Vaccine Safety Datalink. Int J Med Inform. 2019 Jul;127:27-34. doi: 10.1016/j.ijmedinf.2019.04.009. Epub 2019 Apr 13. PubMed

Doyle JD, Chung JR, Kim SS, Gaglani M, Raiyani C, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Foust A, Sessions W, Berman L, Garten RJ, Barnes JR, Wentworth DE, Fry AM, Patel MM, Flannery B. Interim estimates of 2018-19 seasonal influenza vaccine effectiveness - United States, February 2019. MMWR Morb Mortal Wkly Rep. 2019;68(6):135-139. doi: 10.15585/mmwr.mm6806a2. PubMed

McClure DL, Jacobsen SJ, Klein NP, Naleway AL, Kharbanda EO, Glanz JM, Jackson LA, Weintraub ES, McLean HQ. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine. 2019;37(1):76-79. doi: 10.1016/j.vaccine.2018.11.038. Epub 2018 Nov 23. PubMed

Appiah GD, Chung JR, Flannery B, Havers F, Zimmerman RK, Nowalk MP, Monto AS, Martin ET, Gaglani M, Murthy K, Jackson LA, Jackson ML, McLean HQ, Belongia EA, Fry AM. Hospitalization following outpatient medical care for influenza: US Influenza Vaccine Effectiveness Network, 2011-12-2015-16. Influenza Other Respir Viruses. 2019 Mar;13(2):133-137. doi: 10.1111/irv.12616. Epub 2018 Dec 19. PubMed

Shang M, Chung JR, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Fry AM, Flannery B. Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016. Vaccine. 2018 Nov 9. pii: S0264-410X(18)31490-7. doi: 10.1016/j.vaccine.2018.10.093. [Epub ahead of print]. PubMed

Munoz FM, Jackson LA, Swamy GK, Edwards KM, Frey SE, Stephens I, Ault K, Winokur P, Petrie CR, Wolff M, Patel SM, Keitel WA. Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. Vaccine. 2018 Nov 8. pii: S0264-410X(18)31475-0. doi: 10.1016/j.vaccine.2018.10.088. [Epub ahead of print]. PubMed

 

research

man-supine-thermometer-1col.jpg

Clinical trial of H7N9 bird flu vaccine starts at KPWHRI

Dr. Lisa A. Jackson leads national trial to explore improving immune responses to the vaccine.

Read it in News and Events.

research into action

Flu-vaccination-elderly-patients_1col.jpg

Can targeted flu vaccines lower the risk of hospitalization?

Dr. Paula Lozano explains how a Learning Health System project finds Kaiser Permanente Washington members who could benefit most from preventive services.

healthy findings blog

Flu-season-office_1col.jpg

As flu season ramps up, vaccination offers protection

New KPWHRI study helps confirm national guidelines that encourage people with high-risk conditions to get the shot.

Read more in Healthy Findings.

kpwhri in the media

Are we prepared for the next flu pandemic?

U.S. News & World Report, Jan 18, 2018